🩺 Subject
PLUS:
Good morning!
[intro]
Today’s issue takes 5 minutes to read. Only got one? Here’s what to know:
-
Most cancer drugs don’t extend life, investigation finds
-
“Progression-free survival” boosts profits, not patient outcomes
-
FDA approves drugs with minimal evidence of benefit
-
Some $25K/month cancer drugs lack symptom relief data
-
Researchers question core metric used in oncology trials
-
Drugmakers profit before confirming survival impact of treatments
Let’s get into it.
Staying #Up2Date 🚨
1:
Long-form
Hot Off The Press
1: 💊 A sweeping Bloomberg investigation finds that many blockbuster cancer drugs never actually prolong life — and yet still command prices of $25,000+ per month. Since 2000, fewer than half of FDA-approved cancer drugs have shown a survival benefit for any approved use, and even fewer improve symptoms. The metric driving this boom? “Progression-free survival” — a marker some researchers now call arbitrary, but one that’s helped drugmakers generate billions before overall survival data is ever confirmed.
Notable Numbers 🔢
Postcall Picks ✅
Relax
First Question: _____ pregnancy, where a non-viable mass develops in the uterus instead of a healthy embryo
Need a rematch? We’ve got you covered. Check out our Crossword Archive to find every puzzle we’ve ever made, all in one place.
Think you crushed it? Challenge your physician friends to beat your time.
Meme of the Week
Share Postcall, Get Rewards
Help Us Get Better
What'd you think of today's edition? |
That’s all for this issue.
Cheers,
The Postcall team.
